Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study

(2010) J. WINDYGA et al.   HAEMOPHILIA

Inhibitors in previously treated patients: a review of the literature

(2010) C. L. KEMPTON   HAEMOPHILIA

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

(2010) J. OLDENBURG et al.   HAEMOPHILIA

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report

(2010) J. ASTERMARK et al.   HAEMOPHILIA

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

(2010) A. IORIO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment

(2010) Samantha Gouw et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

(2009) Amy Shapiro et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII

(2009) N. BAJWA et al.   HAEMOPHILIA

Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A

(2009) J.-H. YOUNG et al.   HAEMOPHILIA

Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment

(2009) I. DEN UIJL et al.   HAEMOPHILIA

Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII

(2009) C. REA et al.   HAEMOPHILIA

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII

(2009) M. RECHT et al.   HAEMOPHILIA

Purification and characterization of a new recombinant factor VIII (N8)

(2009) L. THIM et al.   HAEMOPHILIA

Functional roles of the factor VIII B domain

(2009) S. W. PIPE   HAEMOPHILIA

Postmarketing surveillance study of KOGENATE®Bayer with Bio-Set®in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution system

(2009) N. VIDOVIC et al.   HAEMOPHILIA

Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study

(2009) P. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials

(2009) M. M. Wilkes et al.   OSTEOPOROSIS INTERNATIONAL

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose

(2008) M. RUBINGER et al.   HAEMOPHILIA

Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto®utilizing a computer-aided diary: a Nordic multicentre study

(2008) P. PETRINI et al.   HAEMOPHILIA

Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

(2008) V. S. BLANCHETTE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS